Evidence map›Paper›PMID 37311803›Full record

ArticleTranslational psychiatry2023

Interactions of calmodulin kinase II with the dopamine transporter facilitate cocaine-induced enhancement of evoked dopamine release.

Jacqueline D Keighron, Jordi Bonaventura, Yang Li, Jae-Won Yang, Emily M DeMarco, Melinda Hersey, Jianjing Cao, Walter Sandtner, Michael Michaelides, Harald H Sitte and 2 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Modafinil, an atypical CNS stimulant?Advances in pharmacology (San Diego, Calif.) · 2024
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Jacqueline D KeighronMedication Development Program, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA.
Jordi BonaventuraBiobehavioral Imaging & Molecular Neuropsychopharmacology Unit, Neuroimaging Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA.ORCID 0000-0002-4745-0151
Yang LiCenter for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Jae-Won YangCenter for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-8928-0130
Emily M DeMarcoMedication Development Program, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA.
Melinda HerseyMedication Development Program, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA.
Jianjing CaoMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA.
Walter SandtnerCenter for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Michael MichaelidesBiobehavioral Imaging & Molecular Neuropsychopharmacology Unit, Neuroimaging Research Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA.ORCID 0000-0003-0398-4917
Harald H SitteCenter for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-1339-7444
Amy Hauck NewmanMedication Development Program, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA.ORCID 0000-0002-4812-9474
Gianluigi TandaMedication Development Program, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA. gtanda@intra.nida.nih.gov.ORCID 0000-0001-9526-9878
National Institute on Drug Abuse · USMedical University of Vienna · AT

Funding

Biobehavioral Imaging and Molecular Neuropsychopharmacology of Substance Abuse MechanismsZIADA000069 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI MICHAELIDES, MICHAEL · 2016 to 2025
$18.9M
Investigation On The Behavior And Related Neuro-Electrochemistry Of Potential Medications For The Treatment Of Substance Use Disorders.ZIADA000611 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI TANDA, GIANLUIGI · 2016 to 2025
$16.0M
Austrian Science Fund FWF P 35589
6 · The paper itself

Abstract

Typical and atypical dopamine uptake inhibitors (DUIs) prefer distinct conformations of the dopamine transporter (DAT) to form ligand-transporter complexes, resulting in markedly different effects on behavior, neurochemistry, and potential for addiction. Here we show that cocaine and cocaine-like typical psychostimulants elicit changes in DA dynamics distinct from those elicited by atypical DUIs, as measured via voltammetry procedures. While both classes of DUIs reduced DA clearance rate, an effect significantly related to their DAT affinity, only typical DUIs elicited a significant stimulation of evoked DA release, an effect unrelated to their DAT affinity, which suggests a mechanism of action other than or in addition to DAT blockade. When given in combination, typical DUIs enhance the stimulatory effects of cocaine on evoked DA release while atypical DUIs blunt them. Pretreatments with an inhibitor of CaMKIIα, a kinase that interacts with DAT and that regulates synapsin phosphorylation and mobilization of reserve pools of DA vesicles, blunted the effects of cocaine on evoked DA release. Our results suggest a role for CaMKIIα in modulating the effects of cocaine on evoked DA release without affecting cocaine inhibition of DA reuptake. This effect is related to a specific DAT conformation stabilized by cocaine. Moreover, atypical DUIs, which prefer a distinct DAT conformation, blunt cocaine's neurochemical and behavioral effects, indicating a unique mechanism underlying their potential as medications for treating psychostimulant use disorder.

Indexed as

Central Nervous System StimulantsCocaineCalcium-Calmodulin-Dependent Protein KinasesDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsCalcium-Calmodulin-Dependent Protein KinasesCentral Nervous System StimulantsCocaineDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake Inhibitors

Identifiers

PMID37311803
PMCPMC10264427
OpenAlexW4380576190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.